- Home
- WBX vs ABOS Comparison
WBX vs ABOS Comparison
Compare WBX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- ABOS
- Stock Information
- Founded
- WBX 2015
- ABOS 1996
- Country
- WBX Spain
- ABOS United States
- Employees
- WBX N/A
- ABOS N/A
- Industry
- WBX Industrial Specialties
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- ABOS Health Care
- Exchange
- WBX Nasdaq
- ABOS Nasdaq
- Market Cap
- WBX 85.1M
- ABOS 72.7M
- IPO Year
- WBX N/A
- ABOS 2021
- Fundamental
- Price
- WBX $5.93
- ABOS $1.51
- Analyst Decision
- WBX Buy
- ABOS Strong Buy
- Analyst Count
- WBX 3
- ABOS 4
- Target Price
- WBX $14.33
- ABOS $6.50
- AVG Volume (30 Days)
- WBX 18.7K
- ABOS 801.7K
- Earning Date
- WBX 07-31-2025
- ABOS 08-12-2025
- Dividend Yield
- WBX N/A
- ABOS N/A
- EPS Growth
- WBX N/A
- ABOS N/A
- EPS
- WBX N/A
- ABOS N/A
- Revenue
- WBX $171,352,140.00
- ABOS N/A
- Revenue This Year
- WBX N/A
- ABOS N/A
- Revenue Next Year
- WBX $44.10
- ABOS N/A
- P/E Ratio
- WBX N/A
- ABOS N/A
- Revenue Growth
- WBX 3.75
- ABOS N/A
- 52 Week Low
- WBX $4.60
- ABOS $0.86
- 52 Week High
- WBX $32.80
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- WBX 83.14
- ABOS 67.39
- Support Level
- WBX $5.92
- ABOS $1.26
- Resistance Level
- WBX $6.25
- ABOS $1.55
- Average True Range (ATR)
- WBX 0.26
- ABOS 0.09
- MACD
- WBX 0.20
- ABOS 0.03
- Stochastic Oscillator
- WBX 91.95
- ABOS 95.58
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.